(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Smoking Cessation
This study is evaluating the safety and effectiveness of a medication to help you stop smoking.
If you are a resident of the Tampa, Fla., area who is a current or former smoker over the age of 40 suffering from smoker's cough, chronic bronchitis or chronic obstructive pulmonary disease (COPD), you may qualify for this clinical trial.
Qualified participants of this study will receive study-related medical care, health assessments and study medications for these symptoms. Health insurance is not needed, and you may be reimbursed for your time and travel.
The research site is in Tampa, Fla.
More information
Please see http://www.centerwatch.com/patient/studies/cat237.html.
-----
Bladder Disorders
This study is a randomized, prospective, double-blind controlled trial to determine if a three-week supply of intravesical alkalized Lidocaine instillation decreases symptoms of overactive bladder (OAB) more than instillation of normal saline.
Women may qualify if they are 18 and older and diagnosed with overactive bladder, defined as urinary frequency (eight or more voids in a 24-hour period, 50 percent of the days of the week) with symptoms of at least three months duration.
The research site is in Evanston, Ill.
More information
Please see http://www.centerwatch.com/patient/studies/cat445.html.
-----
Epilepsy
Medtronic Inc. is sponsoring an investigational study of the Intercept Epilepsy Control System, the company's direct brain stimulation therapy for patients with refractory epilepsy.
Volunteers between the ages of 18 and 65 who have six or more partial-onset seizures a month with or without secondary generalization may qualify.
Successful candidates will continue to receive their epilepsy medications while participating in the trial.
The research site is in St. Louis, Mo.
More information
Please see http://www.centerwatch.com/patient/studies/cat62.html.
-----
Copyright 2006 Thomson CenterWatch. All rights reserved.
